Bionano Genomics, Inc. (BNGO)
| Market Cap | 20.49M +58.0% |
| Revenue (ttm) | 30.18M +10.0% |
| Net Income | -32.16M |
| EPS | -3.37 |
| Shares Out | 11.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,504,077 |
| Open | 1.530 |
| Previous Close | 1.510 |
| Day's Range | 1.500 - 1.855 |
| 52-Week Range | 1.000 - 2.230 |
| Beta | 1.64 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+187.36%) |
| Earnings Date | Aug 10, 2026 |
About BNGO
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by ... [Read more]
Financial Performance
In 2025, Bionano Genomics's revenue was $28.51 million, a decrease of -7.37% compared to the previous year's $30.78 million. Losses were -$26.40 million, -76.44% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for BNGO stock is "Strong Buy" and the 12-month stock price target is $5.0.
News
Bionano Genomics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Optical genome mapping is rapidly advancing clinical genomics by replacing legacy lab standards and expanding its clinical and commercial footprint. Regulatory wins, reimbursement progress, and a strategic focus on high-usage customers are driving strong revenue growth and operational efficiency.
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically signif...
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), toda...
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders, a...
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investme...
Bionano Genomics Earnings Call Transcript: Q2 2026
Q2 2026 saw 21% revenue growth, record flow cell sales, and gross margin improvement to 53%. Growth was driven by increased clinical adoption and utilization among existing clients, with guidance raised for the full year despite manufacturing constraints.
Bionano Genomics Earnings release: Q2 2026
Bionano Genomics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Bionano Genomics Quarterly report: Q2 2026
Bionano Genomics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Bionano Genomics Slides: Q2 2026
Bionano Genomics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. Eastern...
Bionano Genomics appoints Alex Hastie as chief scientific officer
Bionano Genomics (BNGO) announced the appointment of Alex Hastie as its chief scientific officer, or CSO, effective July 20. In this role, Hastie will lead the company’s global scientific strategy,…
Bionano Announces Hiring of Chief Scientific Officer
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientifi...
Bionano Genomics announces studies featuring OGM at 2026 conference
Bionano Genomics (BNGO) announced that studies featuring optical genome mapping, OGM, at the 2026 European Society of Human Genetics, ESHG, conference grew substantially compared to the conference in ...
Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (E...
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that dem...
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "De...
Bionano Genomics announces OGM study of T-cell acute lymphoblastic leukemia
Bionano Genomics (BNGO) announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping, OGM, detected genomic abnormalities in 97.8% of T-cell acute lymphoblast...
Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) det...
Bionano Genomics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4% year-over-year to $6.7 million, with strong consumable sales and improved gross margin. Major reimbursement wins, increased publications, and debt retirement support a positive outlook, with full-year revenue guidance reaffirmed at $30–33 million.
Bionano Genomics Earnings release: Q1 2026
Bionano Genomics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Bionano Genomics Quarterly report: Q1 2026
Bionano Genomics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Bionano Genomics Slides: Q1 2026
Bionano Genomics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Bionano Reports First Quarter 2026 Results and Provides a Business Update
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with fi...
Bionano Genomics files $400M mixed securities shelf
16:04 EDT Bionano Genomics (BNGO) files $400M mixed securities shelf
Bionano Genomics Registration statement: Registration filing
Bionano Genomics filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.